Boehringer Ingelheim’s Zongertinib NDA Accepted by FDA for HER2-Mutated NSCLC
Germany-based Boehringer Ingelheim announced that the US Food and Drug Administration (FDA) has accepted its...
Hepalink Pharmaceutical’s H1710 Heparanase Inhibitor Approved for Phase I Study
China-based Shenzhen Hepalink Pharmaceutical Group Co., Ltd (SHE: 002399) announced that it has received approval...
Henlius Biotech’s Avastin Biosimilar Hanbeitai Approved in Bolivia
Shanghai Henlius Biotech Inc. (HKG: 2696) announced that its biosimilar of Roche’s Avastin (bevacizumab), Hanbeitai,...
Astellas Pharma’s Xospata Wins Regular NMPA Approval for FLT3-Mutated AML
Japan-based Astellas Pharma Inc. (TYO: 4503, OTCMKTS: ALPMY ) announced that the National Medical Products...
Hanx Biopharmaceuticals’ HX009 Receives NMPA Clearance for TNBC Study
Hanx Biopharmaceuticals (Wuhan) Co., Ltd. announced that it has received clearance from the National Medical...
Huadong Medicine’s MediBeacon TGFR System Approved by NMPA for GFR Measurement
China-based Huadong Medicine Co., Ltd (SHE: 000963) announced that it has received marketing approval from...
Sunshine Guojian and Shenyang 3SBio License 612 and 708 Programs for Anti-Tumor Development
China-based Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd and Shenyang 3SBio Co., Ltd, both subsidiaries of...
Antengene to Boost T Cell Engager Platform with AI Investment and DeepSeek Deployment
China-based biopharma Antengene Corp., Ltd (HKG: 6996) announced plans to increase investment in establishing a...
Jiangxi Rimag Group and Xunfei Healthcare Form Strategic Alliance for Smart Healthcare
China-based Jiangxi Rimag Group Co., Ltd (HKG: 2522) announced a strategic alliance with Xunfei Healthcare...
Rendu Biotechnology Partners with Green Apple Medical System for RNA Diagnostics Expansion
Rendu Biotechnology Co., Ltd., (SHA: 688193) a Shanghai-based specialist in RNA molecular diagnostics, has entered...
Genuine Biotech Files for Hong Kong IPO with Azvudine and ZS-1003 in Pipeline
China-based Genuine Biotech Limited has filed for an initial public offering (IPO) on the Hong...
AstraZeneca Faces Class Action Lawsuits Over China Legal Issues
AstraZeneca plc (AZ, NASDAQ: AZN) is facing multiple class action lawsuits in the United States...
Biogen Licenses Stoke Therapeutics’ Zorevunersen for Dravet Syndrome Outside Americas
US-based Biogen Inc. (NASDAQ: BIIB) has entered into a licensing agreement with Stoke Therapeutics, Inc....
TAHO Pharma’s TAH3311 Oral Film Shows Bioequivalence to Eliquis in Study
Taiwan-based TAHO Pharmaceuticals announced positive preliminary results from a pivotal study for its TAH3311 oral...
Sanofi’s Dupixent Receives Priority Review from FDA for Bullous Pemphigoid Treatment
Sanofi (EPA: SAN, NASDAQ: SNY) announced that the US Food and Drug Administration (FDA) has...
CSPC Pharma Licenses SYS 6005 to Radiance Biopharma for Global Markets
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) announced a licensing agreement with Radiance Biopharma, Inc.,...
Biokin Pharmaceutical’s BL-M07D1 Receives NMPA Approval for Phase II/III Study in HER2+ Breast Cancer
China-based Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506) announced that it has received approval from...
Gilead Sciences’ Lenacapavir NDA for HIV Prevention Accepted by FDA for Priority Review
US-based Gilead Sciences Inc. (NASDAQ: GILD) announced that the New Drug Application (NDA) for its...
Merck’s Welireg Wins Conditional EU Approval for VHL Disease and Advanced RCC
US pharmaceutical giant Merck, Sharp & Dohme (MSD, NYSE: MRK) announced that it has received...
GSK and Abbott Announce Leadership Changes in Key Roles
Recent days have seen significant leadership changes at two pharmaceutical giants: UK-based GSK plc (LON:...